January 11, 2021 -- Sanofi has entered into an agreement to acquire monoclonal antibody manufacturer Kymab for an upfront payment of approximately $1.1 billion and up to $350 million in certain milestone achievements.
The transaction will give Sanofi full global rights to KY1005, a fully human monoclonal antibody that binds to the OX40 ligand and has the potential to treat a variety of immune-mediated diseases and inflammatory disorders. The candidate met primary endpoints in a phase IIB clinical trial in moderate to severe atopic dermatitis patients. KY1005 was discovered using Kymab's proprietary integrated platform, IntelliSelect, which contains a full diversity of human antibodies.
Kymab's pipeline also includes other oncology assets including KY1044, an inducible T-cell costimulator (ICOS) agonist monoclonal antibody that is in early clinical development.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
